Cost of care and budget impact of novel first-line treatments in patients with locally advanced or metastatic urothelial carcinoma from the Colombian healthcare system perspective | Synapse
April 16, 2026Expert Review of Pharmacoeconomics & Outcomes Research0 citations
Cost of care and budget impact of novel first-line treatments in patients with locally advanced or metastatic urothelial carcinoma from the Colombian healthcare system perspective
This analysis aims to compare the costs and budget impact of novel first-line treatments for locally advanced or metastatic urothelial carcinoma from a Colombian perspective.
Cost analysis of different treatment combinations
Focus on annual costs of CT+avelumab+BSC, EV+PEM, and NIV+CT
Perspective of the Colombian healthcare system
CT+avelumab+BSC had the lowest annual cost compared to other treatment combinations.
Affordability of CT+avelumab+BSC suggests it may be a favorable option for patients.
The findings indicate potential economic benefits for the healthcare system.
Abstract
CT+avelumab+BSC had the lowest annual cost, suggesting it is affordable versus EV+PEM and NIV+CT.